UN-AUDITED FINANCIAL RESULTS The Board of Director have considered and approved the Un-Audited Financial Results along with Limited Review Report thereon for quarter ended on June 30th, ....

J O H N S O N PHARMACARE LIMITED CIN: L51100GJ1994PLC022388 Registered & Corp. Office Address - I-460, Fourth Floor, Titanium City Centre Mall, Near Sachin Tower, Anand Nagar Road, Satellite, Ahmedabad-380015 Email id: johnsonpharmacare1994@gmail.com sunandshineworldwideltd@gmail.com Date: 13th August, 2026 The Department of Corporate Service BSE Limited PhirozeJeejeebhoy Towers, Dalal Street, Mumbai – 400001. SCRIP CODE: 532154 (JOHNSON PHARMACARE LTD) EQ - ISIN - INE560F01022 Subject: Outcome of Meeting of Board of Directors held on Thursday, 13th August, 2026 at pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/Madam, Pursuant to the provisions of Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the meeting of the Board of Directors of the Company was held today i.e., Thursday 13th August, 2026 which commenced at 05:00 P.M. and concluded at 05:30 P.M. at the registered office of the company at - I-460, Fourth Floor, Titanium City Centre Mall, Near Sachin Tower, Anand Nagar Road, Satellite, Ahmedabad-380015 have considered and approved the following: 1. UN-AUDITED FINANCIAL RESULTS The Board of Director have considered and approved the Un-Audited Financial Results along with Limited Review Report thereon for quarter ended on June 30th, 2026. In this regard, please find enclosed herewith the Un-Audited Financial Results along with Limited Review Report for the quarter ended on June 30th, 2026 pursuant to the Regulation 33 of SEBI (LODR) Regulations, 2015. The copy of the said Un-Audited quarterly financial results along with copy of Limited Review Report by Statutory auditor of the company is enclosed herewith. 2. STATEMENT OF DEVIATION OR VARIATION UNDER REGULATION 32 OF SEBI (LODR) REGULATIONS, 2015 The Board discussed the compliance of Regulation 32 of SEBI (LODR) Regulations, 2015 and is of the view that the same is not applicable to company as the company has not issued equity share by way of Preferential Issue. The undertaking of Non- Applicability of Regulation 32 of SEBI (LODR) Regulations, 2015 for the quarter ended on June 30th, 2026 is enclosed herewith is enclosed herewith. We request you to take the above information on record. Thanking You, Yours Faithfully, For and on behalf of Board of Directors of JOHNSON PHARMACARE LIMITED Nand Kishor Ray Additional Director DIN: 11626638 Date: 13-08-2026 Place: Gujrat (ft( VRSK & ASSOCIATES Chartered Accountants IN D I A Limited Review Report Review repott to Board of Directors of JOHNSON PHARMACARE LIMITED LIMITED REVIEW REPORT ON UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED ON JUNE 30'1''', 2026 OF JOHNSON PIIARMACARE LIMITED. We have reviewed the accompanying statement of unaudited Standalone Financial Results of JOHNSON PHARMACARE LIMITED for the quatter ended 30.06.2026. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a repott on these financial statements based on our review. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (India Accounting Standards) Rules, 2015 and the circular is the responsibility ofthe Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chattered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of any material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. Based on our review conducted as above, subject to the matter given in Emphasis of matter we are of the opinion that the accompanying statement of unaudited standalone financial results, which have not been prepared in accordance with applicable accounting standards i.e. IND AS prescribed under Section 133 ofthe Companies Act, 2013 read with relevant rules issued thereunder. However, nothing has come to our attention which causes us to believe that the accompanying statement of unaudited standalone financial results do not disclosed the information required to be disclosed ins terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 0511 • July, 2016, or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies including the manner in which it is to be disclosed, or that it contains any material misstatement. Partner New Delhi, August 13, 2026 UDIN: 26089823QIJLlK3495 Head Office Faridabad Office South Deihl Office Dwarka Office RohlnlOffice 42, Ward No,18, Basti 173, Sector 21A H1555, LGF, F-6 Malik Building-1 Plot No H-19/53, Pura, Arya Nagar, Rohtak- Faridabad, 121001, Chittaranjan Park, 2 Pocket 6 Sector, Dwarka Sector-7, Rohini, 124001, Haryana, Haryana New Delhi-llOO19 New Delhi-l10075, Delhi-110085 Ph. +91.9310203089 Ph . +919350695696 Ph. +919811022855 Ph. +919811042128 Ph.+91.9310203089 casmittal@gmail,com vrsk.o ffice@gm ail ,com vineet@vrskca ,com ankushfca@gmail.com rrjc_delhi@yahoo. co.in J O H N S O N PHARMACARE LIMITED CIN: L51100GJ1994PLC022388 Registered & Corp. Office Address - I-460, Fourth Floor, Titanium City Centre Mall, Near Sachin Tower, Anand Nagar Road, Satellite, Ahmedabad-380015 Email id: johnsonpharmacare1994@gmail.com sunandshineworldwideltd@gmail.com Date: 13.08.2026 The Department of Corporate ServiÎ BSE Limited PhirozeJeejeebhoy Towers, Dalal Street, Mumbai – 400001. SCRIP CODE: 532154 (JOHNSON PHARMACARE LTD) EQ - ISIN - INE560F01022 Subject: Undertaking for Non- Applicability of Regulation 32 of SEBI (LODR) Regulations, 2015 for the quarter ended on June 30th, 2026. Dear Sir/Madam, As per Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the listed entity shall submit to the stock exchange the following statement(s) for quarter ended on June 30th, 2026 for public issue, rights issue, preferential issue etc. – (a) Indicating deviations, if any, in the use of proceeds from the objects stated in the offer document or explanatory statement to the notice for the general meeting, as applicable; (b) Indicating category wise variation (capital expenditure, sales and marketing, working capital etc.) between projected utilization of funds made by it in its offer document or explanatory statement to the notice for the general meeting, as applicable and the actual utilization of funds. In view of the aforesaid, I, the undersigned, Mr. NAND KISHOR RAY, Director of JOHNSON PHARMACARE LTD hereby certify that Compliances of Regulation 32 of SEBI (LODR) regulations, 2015 is not applicable to the company as the company has not issued any share by way of public issue, right issue, preferential issue etc. for the quarter ended on June 30th, 2026. You are requested to take the above on your records and acknowledge the same. For and on behalf of Board of Directors JOHNSON PHARMACARE LIMITED Nand Kishor Ray Additional Director DIN: 11626638 Date: 13-08-2026 Place: Gujrat